Immunex Corporation

Medimmune Limited

Other

Allozyne, Inc.

Amgen Inc.

Sterling Winthrop Inc.

Immuner Corp.

Kenneth H. Grabstein

Raymond J. Paxton

Dean K. Pettit

Kenneth H Grabstein

Dirk M Anderson

Dean K Pettit

Raymond J Paxton

Charles Rauch

Victor Fung

June R Eisenman

Marcello Marelli

Michael Van Brunt

Natalie Winblade Nairn

Douglas Pat Cerretti

David J Cosman

William Brady

Alf D Larsen

Mark R Alderson

Jeffrey C Johnson

Thomas Graddis

Aijun Wang

Paul J Conlon, Iii

Deepshikha Datta

Paul E Baker

Stephen McCraith

Steven D Gimpel

Michael A Cantrell

Kate N McKereghan

Andrea Wang

Carl J March

David A Tirrell

Gordon E King

Philip J Morrissey

Virginia L Price

Thomas P Hopp

Shirley R Kronheim

Anthony B Troutt

Michael B Widmer

Kurt David Shanebeck

Paul Heffner Slagle

Kenneth Christopher Thornton

LeBris S Quinn

Michael Peter Vanbrunt

Hengyu Xu

Giorgio Dieci

Gordon King

Jeffrey Johnson

The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Amino acid substituted molecules

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Cell lines

There are provided amino acid derivatives of formula V and VI as defined herein which are pyrrolysine analogs for use in bioconjugation processes.

Amino acid derivatives

The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.

Antibody derivatives

There is provided inter alia a DNA construct which comprises a tRNApyl coding sequence and a RNA polymerase III promoter sequence which is capable of acting to express functional tRNApyl sufficiently to support nonsense suppression in a eukaryotic expression system.

Nucleic acid molecules

There are provided pyrrolysine analogs of the formulae (X), (I), (II), (V), (VI), (VII) and (VIII), in which the a, b, d, X, Y, Z, FG, R, R, Rand Rare as defined in the claims, which are useful in bioconjugation processes and mutant proteins containing them.

Modified human interferon-beta polypeptides

Methods of modifying polypeptides comprising non-natural amino acids

Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&#x3b1;-subunit and that are incapable of transducing a signal through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.

Antagonists of interleukin-15

Modified human interferon-&#x3b2; polypeptides

Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.

Method of treating cancer by administering an epithelum-derived T-cell factor

Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&#x3b1;-subunit and that are incapable of transducing a signal through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease,

Polynucleotides encoding epithelium-derived T-cell factor and uses thereof

Growing community of inventors

Mercer Island, WA, United States of America

Kenneth H Grabstein